QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
QQQ   283.85 (+1.18%)
AAPL   142.65 (+1.21%)
MSFT   247.40 (+1.24%)
META   115.33 (+1.23%)
GOOGL   93.71 (-1.30%)
AMZN   90.35 (+2.14%)
TSLA   173.44 (-0.34%)
NVDA   171.69 (+6.51%)
NIO   13.41 (+6.60%)
BABA   94.17 (+6.61%)
AMD   70.47 (+0.47%)
T   19.12 (-0.93%)
MU   55.20 (+2.56%)
CGC   3.09 (-4.63%)
F   13.12 (+0.15%)
GE   83.63 (-1.61%)
DIS   92.55 (+0.43%)
AMC   6.07 (+0.33%)
PYPL   74.22 (-0.27%)
PFE   51.78 (+3.07%)
NFLX   310.26 (+0.60%)
NASDAQ:AMPH

Amphastar Pharmaceuticals - AMPH Stock Forecast, Price & News

$29.20
-0.30 (-1.02%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$28.95
$29.51
50-Day Range
$27.28
$31.27
52-Week Range
$21.13
$44.46
Volume
174,702 shs
Average Volume
395,308 shs
Market Capitalization
$1.41 billion
P/E Ratio
19.60
Dividend Yield
N/A
Price Target
$39.00

Amphastar Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
33.6% Upside
$39.00 Price Target
Short Interest
Healthy
4.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.21
Upright™ Environmental Score
News Sentiment
0.81mentions of Amphastar Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$29,360 Sold Last Quarter
Proj. Earnings Growth
12.95%
From $1.39 to $1.57 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.97 out of 5 stars

Medical Sector

17th out of 1,022 stocks

Pharmaceutical Preparations Industry

7th out of 499 stocks

AMPH stock logo

About Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPH Stock News Headlines

Amphastar: Growth Remains Intact
Amphastar: A Pharmaceutical Growth Stock
Amphastar Pharmaceuticals Inc
AMPH Amphastar Pharmaceuticals, Inc.
See More Headlines
Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPH Company Calendar

Last Earnings
11/08/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/09/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMPH
Employees
1,761
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$39.00
High Stock Price Forecast
$44.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+33.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$62.12 million
Pretax Margin
21.02%

Debt

Sales & Book Value

Annual Sales
$437.77 million
Cash Flow
$1.94 per share
Book Value
$9.31 per share

Miscellaneous

Free Float
34,895,000
Market Cap
$1.41 billion
Optionable
Optionable
Beta
0.71

Key Executives

  • Dr. Ziping  Luo Ph.D.Dr. Ziping Luo Ph.D. (Age 72)
    Chairman, Chief Scientist & COO
    Comp: $1.34M
  • Dr. Yongfeng  Zhang Ph.D.Dr. Yongfeng Zhang Ph.D. (Age 75)
    Co-Founder, Pres, CEO, Chief Scientific Officer & Director
    Comp: $1.93M
  • Mr. William J. Peters M.B.A.Mr. William J. Peters M.B.A. (Age 54)
    CFO, Exec. VP of Fin., Treasurer & Director
    Comp: $1.11M
  • Mr. Jacob Liawatidewi M.B.A. (Age 48)
    Exec. VP of Sales, Marketing & Corp. Admin. Center, Corp. Sec. and Director
    Comp: $773.69k
  • Mr. Rong  Zhou M.S.Mr. Rong Zhou M.S. (Age 63)
    Exec. VP of Production Center
    Comp: $842.77k
  • Dan Dischner M.B.A.
    VP of HR & Corp. Communication
  • Tony Marrs M.B.A.
    M.P.H., Sr. VP of Regulatory Affairs & Clinical Operations
  • Mr. Peter Langosh (Age 69)
    VP of Operational Improvement and VP of Internal Audit













AMPH Stock - Frequently Asked Questions

Should I buy or sell Amphastar Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AMPH shares.
View AMPH analyst ratings
or view top-rated stocks.

What is Amphastar Pharmaceuticals' stock price forecast for 2023?

4 brokerages have issued 1-year price targets for Amphastar Pharmaceuticals' shares. Their AMPH share price forecasts range from $32.00 to $44.00. On average, they anticipate the company's stock price to reach $39.00 in the next twelve months. This suggests a possible upside of 33.6% from the stock's current price.
View analysts price targets for AMPH
or view top-rated stocks among Wall Street analysts.

How have AMPH shares performed in 2022?

Amphastar Pharmaceuticals' stock was trading at $23.29 on January 1st, 2022. Since then, AMPH shares have increased by 25.4% and is now trading at $29.20.
View the best growth stocks for 2022 here
.

When is Amphastar Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our AMPH earnings forecast
.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced its quarterly earnings results on Monday, November, 8th. The company reported $0.46 earnings per share for the quarter, topping analysts' consensus estimates of $0.24 by $0.22. The company had revenue of $112.20 million for the quarter, compared to analysts' expectations of $103 million. Amphastar Pharmaceuticals had a net margin of 15.93% and a trailing twelve-month return on equity of 16.48%. During the same quarter in the prior year, the company earned $0.09 earnings per share.

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend.

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.79%), Federated Hermes Inc. (6.76%), Vanguard Group Inc. (5.39%), Dimensional Fund Advisors LP (3.75%), State Street Corp (3.17%) and Price T Rowe Associates Inc. MD (1.67%). Insiders that own company stock include David Maris, Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, William J Peters and Yakob Liawatidewi.
View institutional ownership trends
.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amphastar Pharmaceuticals' stock price today?

One share of AMPH stock can currently be purchased for approximately $29.20.

How much money does Amphastar Pharmaceuticals make?

Amphastar Pharmaceuticals (NASDAQ:AMPH) has a market capitalization of $1.41 billion and generates $437.77 million in revenue each year. The company earns $62.12 million in net income (profit) each year or $1.49 on an earnings per share basis.

How many employees does Amphastar Pharmaceuticals have?

The company employs 1,761 workers across the globe.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The official website for the company is www.amphastar.com. The company can be reached via phone at (909) 980-9484, via email at jasons@amphastar.com, or via fax at 909-980-8296.

This page (NASDAQ:AMPH) was last updated on 12/8/2022 by MarketBeat.com Staff